Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing perifosine, a novel, potentially first-in-class, oral anti-cancer agent that inhibits key signal transduction pathways, which are associated with programmed cell death, cell growth, cell differentiation and cell survival. Perifosine is currently in Phase III clinical development for both refractory advanced colorectal cancer and multiple myeloma.
Each of the Phase III programs is being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase III clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Please visit www.keryx.com for more information.
Keryx Biopharma - ProActive Corporate Profile - Sep. 2010
Keryx Biopharma Corporate Presentation - Sep. 2010
LifeSci Advisors Research Report - August, 2010
Keryx Biopharmaceuticals (KERX, Buy; Raising Target Price to $8 from $5): Revisiting Perifosine’s Value – Raising Target Price - May 2010
Cancer Stem Cells / Industry Report: Griffin Securities 9/14/09